Summary of characteristics of included studies (n = 70)
| Review characteristics . | n (%) . |
|---|---|
| Indications | |
| DVT/PE | 31 (44.3) |
| Risk reduction of stroke and embolism in patients with nonvalvular AF | 28 (40.0) |
| Cardiovascular event risk reduction | 6 (8.6) |
| Peripheral arterial disease | 2 (2.9) |
| Not applicable | 2 (2.9) |
| Cancer-associated thrombosis | 1 (1.4) |
| Study mentions adherence to PRISMA | |
| Yes | 55 (78.6) |
| No | 15 (21.4) |
| Intervention favorable | |
| Yes | 43 (61.4) |
| No | 17 (24.3) |
| Not applicable | 10 (14.3) |
| Was harms a primary or secondary outcome, or neither? | |
| Primary outcome | 69 (98.6) |
| Secondary outcome | 1 (1.4) |
| Neither | 0 (0.0) |
| Conflict-of-interest statement available | |
| Yes | 34 (48.6) |
| No | 34 (48.6) |
| Not stated | 2 (2.9) |
| Funding source | |
| Not funded | 26 (37.1) |
| Not mentioned | 25 (35.7) |
| Private | 1 (1.4) |
| Public | 17 (24.3) |
| Industry | 1 (1.4) |
| AMSTAR-2 rating∗ | |
| High | 0 (0.0) |
| Moderate | 0 (0.0) |
| Low | 1 (1.4) |
| Critically low | 69 (98.6) |
| Review characteristics . | n (%) . |
|---|---|
| Indications | |
| DVT/PE | 31 (44.3) |
| Risk reduction of stroke and embolism in patients with nonvalvular AF | 28 (40.0) |
| Cardiovascular event risk reduction | 6 (8.6) |
| Peripheral arterial disease | 2 (2.9) |
| Not applicable | 2 (2.9) |
| Cancer-associated thrombosis | 1 (1.4) |
| Study mentions adherence to PRISMA | |
| Yes | 55 (78.6) |
| No | 15 (21.4) |
| Intervention favorable | |
| Yes | 43 (61.4) |
| No | 17 (24.3) |
| Not applicable | 10 (14.3) |
| Was harms a primary or secondary outcome, or neither? | |
| Primary outcome | 69 (98.6) |
| Secondary outcome | 1 (1.4) |
| Neither | 0 (0.0) |
| Conflict-of-interest statement available | |
| Yes | 34 (48.6) |
| No | 34 (48.6) |
| Not stated | 2 (2.9) |
| Funding source | |
| Not funded | 26 (37.1) |
| Not mentioned | 25 (35.7) |
| Private | 1 (1.4) |
| Public | 17 (24.3) |
| Industry | 1 (1.4) |
| AMSTAR-2 rating∗ | |
| High | 0 (0.0) |
| Moderate | 0 (0.0) |
| Low | 1 (1.4) |
| Critically low | 69 (98.6) |
DVT, deep vein thrombosis; PE, phycoerythrin.
A measurement tool to assess SRs.